| Bioactivity | Ampreloxetine (TD-9855) TFA is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine TFA has the potential for the research of neurogenic orthostatic hypotension[1][2]. |
| In Vivo | Ampreloxetine (0.3, 1, 5, 10, 30, 60 mg/kg; p.o.; single dose) TFA 在大鼠血浆中的 EC50 值分别为 11.7ng/mL 和 50.8ng/mL[1]。 Animal Model: |
| Name | Ampreloxetine TFA |
| Formula | C20H19F6NO3 |
| Molar Mass | 435.36 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Smith JA, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2):pyu027. [2]. Kaufmann H, et al. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res. 2021 Dec;31(6):699-711. |